253 related articles for article (PubMed ID: 28535104)
21. Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
Saluja R; Everest L; Cheng S; Cheung M; Chan KKW
JAMA Oncol; 2019 Aug; 5(8):1188-1194. PubMed ID: 31095255
[TBL] [Abstract][Full Text] [Related]
22. Association between control group therapy and magnitude of clinical benefit of cancer drugs.
Molto C; Tibau A; Bujosa A; Tapia JC; Mittal A; Tamimi F; Amir E
Sci Rep; 2022 Dec; 12(1):21342. PubMed ID: 36494465
[TBL] [Abstract][Full Text] [Related]
23. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
Schafer J; Galante D; Shafrin J
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
[TBL] [Abstract][Full Text] [Related]
24. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
25. Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?
Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
JCO Oncol Pract; 2020 Aug; 16(8):e779-e790. PubMed ID: 32196423
[TBL] [Abstract][Full Text] [Related]
26. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS.
Jiang Q; Feng M; Li Y; Lang J; Wei H; Yu T
Front Pharmacol; 2020; 11():574511. PubMed ID: 33390946
[No Abstract] [Full Text] [Related]
27. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
28. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
[TBL] [Abstract][Full Text] [Related]
29. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
30. A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study.
Büsch CA; Kirchner M; Behnisch R; Kieser M
Med Decis Making; 2024 May; 44(4):365-379. PubMed ID: 38721872
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
[TBL] [Abstract][Full Text] [Related]
32. Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
Luo J; Ou S; Wei H; Qin X; Peng R; Wang S; Jiang Q
Front Public Health; 2023; 11():1109668. PubMed ID: 36908440
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
[TBL] [Abstract][Full Text] [Related]
34. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
[No Abstract] [Full Text] [Related]
35. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
37. Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies.
Li J; Vivot A; Alter L; Durand-Zaleski I
Expert Rev Pharmacoecon Outcomes Res; 2020 Aug; 20(4):405-409. PubMed ID: 31240965
[TBL] [Abstract][Full Text] [Related]
38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
39. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
[No Abstract] [Full Text] [Related]
40. The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.
Lin S; Huang Y; Dong L; Li M; Wang Y; Gu D; Wu W; Nian D; Luo S; Huang X; Xu X; Weng X
Front Pharmacol; 2023; 14():1114304. PubMed ID: 36909180
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
